This Article Abstract Full Text (PDF) All Versions of this Article: 146/11/4690    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, G. Articles by Liu, Z. Search for Related Content PubMed PubMed Citation Articles by Li, G. Articles by Liu, Z.

Insulin at Physiological Concentrations Selectively Activates Insulin But Not Insulin-Like Growth Factor I (IGF-I) or Insulin/IGF-I Hybrid Receptors in Endothelial Cells

Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Virginia Health System, Charlottesville, Virginia 22908-1410

Address all correspondence and requests for reprints to: Zhenqi Liu, M.D., Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Virginia Health System, P.O. Box 801410, Charlottesville, Virginia 22908-1410. E-mail: zl3e{at}virginia.edu.

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
In muscle, physiologic hyperinsulinemia, presumably acting on endothelial cells (ECs), dilates arterioles and regulates both total blood flow and capillary recruitment, which in turn influences glucose disposal. In cultured ECs, however, supraphysiological (e.g. 10 nM) insulin concentrations are typically used to study insulin receptor (IR) signaling pathways and nitric oxide generation. IGF-I receptors (IGF-IRs) are more abundant than IR in ECs, and they also respond to high concentrations of insulin. To address whether IR mediates responses to physiologic insulin stimuli, we examined the insulin concentration dependence of IR and IGF-IR-mediated insulin signaling in bovine aortic ECs (bAECs). We also assessed whether insulin/IGF-I hybrid receptors were present in bAECs. Insulin, at 100–500 pM, significantly stimulated the phosphorylation of IRß, Akt1, endothelial isoform of nitric oxide synthase, and ERK 1/2 but not the IGF-IRß subunit. At concentrations 1–5 nM or greater, insulin dose-dependently enhanced the tyrosine phosphorylation of IGF-IRß, and this was inhibited by IGF-IR neutralizing antibody. In addition, immunoprecipitation of IRß pulled down the IGF-IRß, and the IRß immunocytochemically colocalized with IGF-IRß, suggesting that ECs have insulin/IGF-I hybrid receptors. We conclude that: 1) insulin at physiological concentrations selectively activates IR signaling in bAECs; 2) bAECs express IGF-IR and insulin/IGF-I hybrid receptors in addition to IR; 3) high concentrations of insulin (1–5 nM) activate IGF-IR and hybrid receptors as well as IR; and 4) this crossover activation can confound interpretation of studies of insulin action in ECs when high insulin concentrations are used.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
AMONG THEIR MULTIPLE functions, endothelial cells (ECs) are thought to mediate many of the vascular actions of insulin. These actions include increasing the compliance of conduit blood vessels (1), dilation of resistance arterioles (2, 3), and relaxation of small precapillary arterioles (4, 5). The latter two actions can affect glucose disposal (6, 7, 8). Furthermore, insulin’s vascular actions are impaired in both naturally occurring (e.g. obesity, type 2 diabetes) (9, 10, 11) and experimentally induced (free fatty acid infusion, TNF treatment) (12, 13, 14, 15) states of insulin resistance. Clinically, endothelial dysfunction is an early marker of vascular disease, which is itself more prevalent in the diabetic population (16, 17). However, our mechanistic understanding of insulin’s direct actions on the endothelium remains poorly characterized. This arises in part because the measures used to characterize insulin action in vivo only indirectly report on the role of the endothelium. Thus, insulin-induced smooth muscle relaxation may be due to endothelial action of insulin; insulin acting directly on smooth muscle; or, in the case of skeletal muscle, insulin acting on skeletal muscle that in turn affects vasodilation. Each of these cells possesses insulin receptors (IRs) (18) and one or another isoform of nitric oxide synthase (19). We recently reported that insulin-mediated capillary recruitment preceded activation of insulin signaling pathways within rat muscle, thereby arguing against myocyte involvement in insulin-mediated capillary recruitment (7). The relaxation of resistance arterioles and increases of total muscle blood flow occur slowly and require up to several hours of insulin exposure (18, 20); hence, nonendothelial effects of insulin are not only possibly but also very likely involved.

This underscores the importance of direct examination of insulin’s action on ECs. Evidence for a direct action of insulin on the ECs comes first from the demonstration that these cells possess IR, insulin can stimulate receptor autophosphorylation, and insulin also affects downstream signaling pathways including the phosphatidylinositol 3-kinase (PI3-kinase) pathway (21, 22, 23, 24, 25). Activation of this pathway leads to the activation of protein kinase B (or Akt), which can phosphorylate and activate the endothelial isoform of nitric oxide synthase (eNOS). These findings support a direct role of the EC in the vascular actions of insulin described above. However, it is also true that the majority of studies of insulin action on ECs have used unphysiologically high concentrations of insulin (typically 10 nM) (21, 22, 23, 24, 25, 26). This alone would raise questions regarding the physiological relevance of observations made in these cells. This concern is rendered all the more relevant by the observation that ECs express greater numbers of receptors for IGF-I than insulin (27), and insulin at supraphysiological concentrations can cross-react with IGF-I receptors (IGF-IR). In addition, a recent report suggests that human umbilical vein ECs (HUVEC), like many other insulin-sensitive tissues, express hybrid receptors (28) that are composed of one - and one ß-subunit of the IR and a corresponding - and ß-subunit of the IGF-IR. When studied in other tissues, these hybrid receptors appear to have binding characteristics toward insulin more akin to that of the IGF-IR (29, 30, 31).

The major purpose of the present study was to address whether ECs could respond to insulin at physiologically relevant concentrations at which action through the IGF-IR could be excluded. We report that insulin selectively stimulates the tyrosine (Tyr) phosphorylation of its own receptor ß-subunit and activates downstream signaling pathways in cultured bovine aortic ECs (bAECs). This occurs at insulin concentrations that do not Tyr-phosphorylate the IGF-IR ß-subunit. We also confirm that bAECs, like several other insulin sensitive tissues, may possess hybrid insulin/IGF-I receptors. These findings underscore that dissecting the specific actions of insulin within the ECs requires careful attention to the insulin concentration to avoid confounding contributions from the IGF-IR or insulin/IGF-I hybrid receptors.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Culture of bAECs
Cells in primary culture were purchased from Cambrex BioSciences Walkersville, Inc. (Walkersville, MD) and cultured in endothelial basic media, which was supplemented with 5% fetal bovine serum, bovine brain extract, human EGF (10 ng/ml), gentamicin sulfate (50 µg/ml), amphotericin-B (50 ng/ml), and hydrocortisone (1 µg/ml). Cells between passages 3 and 8 were used for experiments after growing to 75–80% confluence, with or without serum starvation for 16–18 h. Cells were washed with ice-cold 1x PBS solution twice and then lysed and sonicated using an XL2020 sonicator (Fisher Scientific, Pittsburgh, PA) in ice-cold lysis buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P-40, 0.25% sodium deoxycholate, 1 mM EGTA, 1 mM sodium orthovanadate, 1 mM NaF, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin, and 1 mM phenylmethylsulfonyl fluoride]. Cell lysates were centrifuged for 10 min at 4 C (20,000 x g), and the supernatants were used for either immunoprecipitation or Western blotting.

Immunoprecipitation of IRß and IGF-IRß
Aliquots of supernatant containing 500-1000 µg protein in 1000 µl lysis buffer were incubated with 25 µl primary antibody against either IRß or IGF-IRß (2.5 µg/ml) overnight at 4 C. Protein A/G plus IgG-agarose was then added and the mixture was kept at 4 C for 1 h with gentle rocking. After washing six times with lysis buffer, the beads were spun down (1000 x g for 30 sec), resuspended in 50 µl 2x sample buffer [375 mM Tris-HCl (pH 6.8), 12% sodium dodecyl sulfate, 60% glycerol, 300 mM dithiothreitol, and 0.06% bromophenol blue], and boiled for 5 min.

Immunoblotting
Equal amount of IRß or IGF-IRß immunoprecipitate or aliquots of cell lysate supernatant containing approximately 100 µg protein were diluted with an equal volume of sodium dodecyl sulfate sample buffer and electrophoresed on a 10% polyacrylamide gel, transferred to nitrocellulose, and blocked with 5% low-fat milk in Tris-buffered saline plus Tween 20. Subsequently membranes were probed with antibodies against IRß, IGF-IRß, phospho-Tyr (p-Tyr) (Santa Cruz Biotechnology, Santa Cruz, CA), phospho-Akt1 (Ser ⁴⁷³) (Upstate Cell Signaling, Lake Placid, NY), phospho-ERK1/2, or phospho-eNOS (Ser¹¹⁷⁷) (New England BioLabs, Beverly, MA) for 1 h at 4 C. This was followed by a donkey antirabbit IgG coupled to horseradish peroxidase, and the blots were developed using enhanced chemiluminescence detection (Amersham Life Sciences, Piscataway, NJ). To assure equal loading of proteins, membranes probed with antibodies against above-mentioned phosphoproteins were stripped with restore Western blot stripping buffer (Pierce Chemical Co., Rockford, IL) and reprobed with antibodies against IRß, IGF-IRß, Akt1, ERK1/2, or eNOS as appropriate.

Immunocytochemical staining
The double-staining protocols were the same as we described previously (32, 33). Briefly, bAECs were grown in slide chambers as described above. Cells were fixed with cold methanol for 10 min at –20 C, washed three times in PBS, permeabilized in PBS containing 0.05% Triton X-100 and 1% horse serum for 30 min at room temperature, and incubated with mouse monoclonal anti-IRß antibody (Chemicon International, Temecula, CA; 1:50) and rabbit polyclonal antibody against IGF-IRß (Santa Cruz Biotechnology; 1:50) (double labeling) overnight at 4 C. After washing three times with PBS, cells were then incubated with species-specific secondary antibodies conjugated with a fluorochrome (either Cy2 or Cy3) (Jackson ImmunoResearch, West Grove, PA) at 1:200 dilutions for 45 min at room temperature, washed three more times with PBS, and coverslipped with the antifade mounting medium.

Confocal imaging
The double-immunocytochemical labeling was examined simultaneously using a two-color BX50 WI confocal microscope (Olympus, Tokyo, Japan) equipped with krypton and argon laser as described previously (32, 33). An x-y-z-axis scanning method was employed. The images were scanned through up to x100 objectives, acquired at a resolution of 1024 x 1024 pixels, and stored in 24-bit TIFF format. To address whether the immunoreactivity was located within the cells, a series of optical sections at a thickness of less than 0.1 µm was acquired from the top to the bottom of the cells along the z-axis.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Time course of insulin action in cultured bAECs
To examine the time course of IR activation in cultured bAECs, cells were incubated with 100 nM insulin for 0, 10, 20, 30, 40, and 50 min. We used 100 nM insulin because insulin at this concentration has repeatedly been shown to strongly stimulate phosphorylation of Akt, eNOS, and other insulin-activated pathways. Cells were then processed as described above, immunoprecipitated with anti-IRß, and immunoblotted with anti-p-Tyr. As shown in Fig. 1, insulin stimulated IRß Tyr phosphorylation within 10 min, and this reached a maximum at 30 min and declined thereafter. Based on this finding, we used 30 min incubation time for all subsequent experiments.

View larger version (21K): [in this window] [in a new window]   FIG. 1. Time course of insulin-stimulated IRß Tyr phosphorylation in cultured bAECs. Cells were incubated with 100 nM insulin for the times indicated; cell lysates were immunoprecipitated with anti-IRß and then immunoblotted with either anti-p-Tyr or anti-IRß. Gels are representatives of three different experiments.

View larger version (62K): [in this window] [in a new window]   FIG. 2. Insulin at physiological concentrations stimulates IRß Tyr phosphorylation in cultured bAECs. A, Tyr phosphorylation of IRß. B, Phosphorylation of Akt1. C, Phosphorylation of ERK1/2. D, Phosphorylation of eNOS. Each gel is a representative of three to four experiments. IP, Immunoprecipitation; IB, immunoblot.

bAECs express both IGF-IR and insulin/IGF-I hybrid receptors
ECs possess abundant IGF-IR (27), and studies done in cell lines other than ECs have demonstrated a cross-activation of IGF-IR when insulin is present at high concentrations. Also, a recent report suggests that HUVEC, like muscle and adipose tissue, expresses insulin/IGF-I hybrid receptors (28). To ascertain whether bAECs also express insulin/IGF-I hybrid receptors, we immunoprecipitated cell lysates with either anti-IRß or anti-IGF-IRß and then probed with antibodies against either IRß or IGF-IRß. As shown in Fig. 3, IGF-IRß clearly coprecipitated with IRß, and a significant amount of IRß coprecipitated with IGF-IRß. Because the IRß and IGF-IRß antibodies used do not cross-react with IGF-IRß and IRß, respectively, our data suggest that in addition to IR and IGF-IR, insulin/IGF-I hybrid receptors are present in cultured bAECs.

View larger version (33K): [in this window] [in a new window]   FIG. 3. bAECs express abundant IGF-IR and insulin/IGF-I hybrid receptors. Gels are representatives of three different experiments. IP, Immunoprecipitation; IB, immunoblot.

View larger version (15K): [in this window] [in a new window]   FIG. 4. Confocal images (optical section < 0.1 µm) showing bAECs labeled by antibody against IGF-IR (A, revealed by Cy3, red), IR (B, revealed by Cy2, green), or both (C, merged by A and B). Yellow color in C denotes the presence of both IGF-IR and IR immunoreactivity (arrow).

View larger version (47K): [in this window] [in a new window]   FIG. 5. Insulin at high concentrations stimulates IGF-IR Tyr phosphorylation. A, Insulin dose-dependently stimulates IGF-IRß phosphorylation from 0.5 to 100 nM. B, IGF-IR neutralizing antibody IGF-IR (Ab-3) blocks insulin-stimulated IGF-IRß but not IRß or Akt1 phosphorylation. Gels are representatives of three to four different experiments. IP, Immunoprecipitation; IB, immunoblot.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
The current study provides the first clear demonstration that insulin, at concentrations well within the physiologic range, can stimulate the tyrosine phosphorylation of its own receptors on ECs and in addition phosphorylates relevant regulatory proteins within the PI3-kinase and ERK signaling pathways. Both pathways are downstream of IR and are pivotal in mediating insulin’s multiple cellular actions. Whereas we also confirmed that ECs possess IGF-IR and hybrid insulin/IGF-I receptors in addition to IR, these receptors are likewise activated by insulin but at higher insulin concentrations.

Considering first what was seen when the ECs were exposed to physiologic insulin concentrations, it is clear that this was sufficient to substantially activate downstream insulin signaling including at least Akt1 and eNOS as well as ERK1/2. This was seen with insulin concentrations that had no effect to enhance the tyrosine phosphorylation of the IGF-IRß subunit. This certainly suggests that these actions result from insulin stimulation of its own receptor tyrosine kinase. That preincubation of ECs with IGF-IR neutralizing antibody completely abolished insulin-stimulated IGF-IRß Tyr phosphorylation but not IRß Tyr phosphorylation or Akt1 serine phosphorylation confirms that insulin indeed can activate its receptor kinase activity and downstream signaling independent of IGF-IR.

These results support the hypothesis that insulin’s physiologic actions on the vasculature, which contribute to insulin-mediated glucose disposal, may indeed result, at least in part, from direct actions on the ECs. For example, recent results from in vivo studies in our laboratory indicate that very modest increases in plasma insulin concentration from 60 to 300 pM exert a nitric oxide (NO)-dependent action to recruit capillaries within skeletal muscle (6, 7, 34). These effects occur very promptly, being significant by 10 min and fully established by 30 min, a time course similar to that observed here for Tyr phosphorylation of IR. Furthermore, these in vivo responses precede any discernible metabolic effect of insulin on skeletal muscle, implying a more direct effect on the vasculature. Previous reports that insulin augments endothelial NO production or phosphorylation of Akt or eNOS have involved using insulin at concentrations of 10 nM or greater (21, 22, 24, 25). Thus, the current results in cultured bAECs are quite consistent with what has been seen in vivo and would be consonant with the hypothesis that insulin can act directly on the endothelium at physiologic concentrations to exert NO-mediated biologic effects. These observations, of course, in no way exclude the possibilities that insulin might also affect smooth muscle cells and that direct actions on these cells may be importantly involved in insulin’s in vivo vascular action.

The concept that insulin has an important physiologic action on the ECs is perhaps challenged by the observation that mice deficient in IR selectively in the ECs (VENIRKO mice) are insulin resistant only when studied on a low-salt diet (35). However, because targeted deletion of IR in skeletal muscle also minimally affects glucose metabolism, it is clear that either other developmental compensation can occur (expression of both eNOS and endothelin-1 are altered in VENIRKO mice) or our ability to finely assess significant but not gross dysfunction is not in hand. It is obviously easier to dismiss the action of insulin on ECs as of no physiologic significance if it is seen only at supraphysiologic insulin concentrations. Insulin’s action on ECs has previously been most thoroughly studied by Quon and colleagues using HUVECs (21, 22, 24, 25). That laboratory demonstrated that insulin induces phosphorylation of IR, Akt, and eNOS. The latter two actions are blunted by inhibition of PI-3-kinase. However, in their studies no significant effect was seen at insulin concentrations less than 10 nM, and its effect was half maximal at approximately 500 nM. Whether this much reduced insulin sensitivity, compared with our current work, relates to differences between bovine aortic and human venous cells or other specific aspects of the experimental protocol is uncertain. In a number of other studies using either pulmonary arterial (26) or aortic ECs (36, 37), clear demonstration of effects of insulin again were seen only with unphysiologically high concentrations. We would emphasize that findings from our current work in bAECs fully support the conclusions reached by Quon and colleagues from studies using higher insulin concentrations in HUVECs.

Our observation that higher concentrations of insulin (1–5 nM) significantly stimulate IGF-IRß tyrosine phosphorylation confirmed the crossover effect of insulin described in other tissues. Generally, in vitro studies of the IGF-IR suggest that it has a more than 100 times lesser relative affinity for insulin than does IR, and the insulin/IGF-I hybrid receptors behave similarly to IGF-IR in insulin or IGF-I binding affinity (38, 39). In the current study, we saw stimulation of the tyrosine phosphorylation of IGF-IR in ECs when insulin concentrations were between 1 and 5 nM or 10- to 50-fold above the lowest insulin dose that stimulated IRß Tyr phosphorylation. It is possible that this reflects, at least in part, a greater abundance of IGF-IR and insulin/IGF-I hybrid receptors, compared with IR in the ECs. IGF-I, like insulin, can stimulate NO production in cultured ECs (40) and increase skeletal muscle blood flow in humans (41).

Others have reported that the IGF-IR is as much as 10-fold more abundant than IR on ECs (at least in HUVECs) (42). The contribution of hybrid receptors to this estimate is not known. Our results from IGF-IRß and IRß reciprocal immunoprecipitation and immunoblotting study (Fig. 3) and immunocytochemical staining/confocal microscopy (Fig. 4) suggested that indeed there are ample insulin/IGF-I hybrid receptors in ECs as well. However, this technique cannot exclude the possibility that the IGF-I and insulin receptors are part of a macromolecular complex that is not disrupted by the lysis procedure and they are being jointly immunoprecipitated as part of a larger complex. We did not attempt to quantitate the relative proportions of insulin, IGF-I, and insulin/IGF-I hybrid receptors present on ECs. We did, however, attempt to define the contribution of IR and IGF-IR or hybrid receptors to insulin signaling by varying insulin concentrations throughout the physiologic and pharmacologic range. Interestingly, we did not observe a further increase in IRß Tyr phosphorylation when insulin was present at pharmacological concentrations. One might assume that Tyr phosphorylation of the IRß subunits from the insulin/IGF-I hybrid receptors should result in higher signal intensity. Whether this is due to the semiquantitative nature of the Western blotting technique, some more complex interaction between the subunits of the hybrid receptor, or a decline in native IR phosphorylation at very high insulin concentrations was not investigated.

We note that whereas insulin-stimulated tyrosine phosphorylation of its own receptor appeared to reach a maximum between 0.2 and 0.5 nM, phosphorylation of Akt and eNOS continued to increase up to insulin concentrations of 100 nM. This also appeared to occur in the presence of IGF-IR blocking antibody (Fig. 5B). Several factors may account for this. First, because the insulin concentration is further raised, it is possible that insulin is competing with the IGF-I blocking antibody because both compounds associate reversibly with the IGF-IR; second, the hybrid receptors we report (see also Ref.28) may be less sensitive to the IGF-IR blocking antibody than is the native IGF-IR, allowing some further stimulation of the IGF-I/insulin signal transduction pathways at high insulin concentrations. In addition, because there is both amplification of signal within the PI3-kinase/Akt pathway and cross talk between the various arms of IR signaling cascades (e.g. the ERK pathway and the Akt pathway), there may not be a one-to-one quantitative correspondence between IR phosphorylation and phosphorylation of downstream signaling molecules. Finally, Western blotting is by its nature a semiquantitative method that also might prevent a one-to-one correspondence between IR and Akt or eNOS phosphorylation.

In conclusion, bAECs express IGF-IR and insulin/IGF-I hybrid receptors in addition to IR, but the phosphorylation/activation of IR alone is very sensitive to physiological doses of insulin. High doses of insulin cross-activate IGF-IR and insulin/IGF-I hybrid receptors, and this may confound interpretation of previous studies of high-dose insulin action on ECs. The ability of insulin to both phosphorylate its receptor and activate downstream signaling pathways at insulin concentrations well within the physiological range supports the consideration of these cells as a potentially important insulin target tissue. Nevertheless, our data do not clarify whether the vascular action of insulin is impaired in pathological conditions associated with insulin resistance, (e.g. obesity and type 2 diabetes mellitus). Much further study is needed to define this relationship, if any.

	Footnotes

 
This work was supported by a research grant from the American Diabetes Association (to Z.L.) and National Institutes of Health Grants RR-15540 (to Z.L.), DK-38578 and DK-54058 (to E.J.B.), and P30-DK063609 (to the University of Virginia Diabetes Endocrinology Research Center).

First Published Online August 11, 2005

Abbreviations: bAEC, Bovine aortic EC; EC, endothelial cell; eNOS, endothelial isoform of nitric oxide synthase; HUVEC, human umbilical vein EC; IGF-IR, IGF-I receptor; IR, insulin receptor; NO, nitric oxide; PI3-kinase, phosphatidylinositol 3-kinase; p-Tyr, phospho-Tyr.

Received April 28, 2005.

Accepted for publication July 29, 2005.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Westerbacka J, Vehkavaara S, Bergholm R, Wilkinson I, Cockcroft J, Yki-Jarvinen H 1999 Marked resistance of the ability of insulin to decrease arterial stiffness characterizes human obesity. Diabetes 48:821–827[Abstract]
2. Nuutila P, Raitakari M, Laine H, Kirvela O, Takala T, Utriainen T, Makimattila S, Pitkanen O-P, Ruotsalainen U, Iida H, Knuuti J, Yki-Jarvinen H 1996 Role of blood flow in regulating insulin-stimulated glucose uptake in humans. Studies using bradykinin, [¹⁵O]water, and [¹⁸F]fluoro-deoxy-glucose and positron emission tomography. J Clin Invest 97:1741–1747[Medline]
3. Baron AD, Laakso M, Brechtel G, Edelman SV 1991 Mechanism of insulin resistance in insulin-dependent diabetes mellitus: a major role for reduced skeletal muscle blood flow. J Clin Endocrinol Metab 73:637–643[Abstract]
4. Rattigan S, Clark MG, Barrett EJ 1997 Hemodynamic actions of insulin in rat skeletal muscle: evidence for capillary recruitment. Diabetes 46:1381–1388[Abstract]
5. Coggins M, Lindner J, Rattigan S, Jahn L, Fasy E, Kaul S, Barrett E 2001 Physiologic hyperinsulinemia enhances human skeletal muscle perfusion by capillary recruitment. Diabetes 50:2682–2690[Abstract/Free Full Text]
6. Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S 2003 Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab 285:E123–E129
7. Vincent MA, Clerk LH, Lindner JR, Klibanov AL, Clark MG, Rattigan S, Barrett EJ 2004 Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes 53:1418–1423[Abstract/Free Full Text]
8. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD 1994 Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 94:1172–1179
9. Laakso M, Edelman SV, Brechtel G, Baron AD 1990 Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 85:1844–1852
10. Laakso M, Edelman SV, Brechtel G, Baron AD 1992 Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes 41:1076–1083[Abstract]
11. Baron AD, Brechtel-Hook G, Johnson A, Hardin D 1993 Skeletal muscle blood flow. A possible link between insulin resistance and blood pressure. Hypertension 21:129–135[Abstract/Free Full Text]
12. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD 1997 Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 100:1230–1239[Medline]
13. Youd JM, Rattigan S, Clark MG 2000 Acute impairment of insulin-mediated capillary recruitment and glucose uptake in rat skeletal muscle in vivo by TNF-. Diabetes 49:1904–1909[Abstract]
14. Clerk LH, Rattigan S, Clark MG 2002 Lipid infusion impairs physiologic insulin-mediated capillary recruitment and muscle glucose uptake in vivo. Diabetes 51:1138–1145[Abstract/Free Full Text]
15. Wallis MG, Wheatley CM, Rattigan S, Barrett EJ, Clark ADH, Clark MG 2002 Insulin-mediated hemodynamic changes are impaired in muscle of Zucker obese rats. Diabetes 51:3492–3498[Abstract/Free Full Text]
16. Makimattila S, Yki-Jarvinen H 2002 Endothelial dysfunction in human diabetes. Current Diab Rep 2:26–36
17. Vehkavaara S, Seppala-Lindroos A, Westerbacka J, Groop PH, Yki-Jarvinen H 1999 In vivo endothelial dysfunction characterizes patients with impaired fasting glucose. Diabetes Care 22:2055–2060[Abstract/Free Full Text]
18. King GL, Buzney SM, Kahn CR, Hetu N, Buchwald S, Macdonald SG, Rand LI 1983 Differential responsiveness to insulin of endothelial and support cells from micro- and macrovessels. J Clin Invest 71:974–979
19. Segal SS, Brett SE, Sessa WC 1999 Codistribution of NOS and caveolin throughout peripheral vasculature and skeletal muscle of hamsters. Am J Physiol Heart Circ Physiol 277:H1167–H1177
20. Yki-Jarvinen H, Utriainen T 1998 Insulin-induced vasodilatation: physiology or pharmacology? Diabetologia 41:369–379[CrossRef][Medline]
21. Zeng G, Nystrom FH, Ravichandran LV, Cong L-N, Kirby M, Mostowski H, Quon MJ 2000 Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101:1539–1545[Abstract/Free Full Text]
22. Zeng G, Quon MJ 1996 Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 98:894–898[Medline]
23. Montagnani M, Chen H, Barr VA, Quon MJ 2001 Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser1179. J Biol Chem 276:30392–30398[Abstract/Free Full Text]
24. Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN, Johansen M, Kucik DF, Quon MJ, Draznin B 2002 Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem 277:1794–1799[Abstract/Free Full Text]
25. Montagnani M, Ravichandran LV, Chen H, Esposito DL, Quon MJ 2002 Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol Endocrinol 16:1931–1942[Abstract/Free Full Text]
26. Lynn MA, Rupnow HL, Kleinhenz DJ, Kanner WA, Dudley SC, Hart CM 2004 Fatty acids differentially modulate insulin-stimulated endothelial nitric oxide production by an Akt-independent pathway. J Invest Med 52:129–136[Medline]
27. Chisalita SI, Arnqvist HJ 2004 Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells. Am J Physiol Endocrinol Metab 286:E896–E901
28. Dekker Nitert M, Chisalita SI, Olsson K, Bornfeldt KE, Arnqvist HJ 2005 IGF-I/insulin hybrid receptors in human endothelial cells. Mol Cell Endocrinol 229:31–37[CrossRef][Medline]
29. Pessin JE, Frattali AL 1994 Structure-function properties of insulin/IGF-I hybrid receptors. In: LeRoith D, Draznin B, eds. Molecular biology of diabetes, part II. Totowa, NJ: Humana Press; 413–426
30. Bailyes EM, Nave BT, Soos MA, Orr SR, Hayward AC, Siddle K 1997 Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J 327:209–215
31. Federici M, Zucaro L, Porzio O, Massoud R, Borboni P, Lauro D, Sesti G 1996 Increased expression of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of noninsulin-dependent diabetes mellitus subjects. J Clin Invest 98:2887–2893[Medline]
32. Wang H, Stornetta RL, Rosin DL, Guyenet PG 2001 Neurokinin-1 receptor-immunoreactive neurons of the ventral respiratory group in the rat. J Comp Neurol 434:128–146[CrossRef][Medline]
33. Wang H, Weston MC, McQuiston TJ, Stornetta RL, Guyenet PG 2003 Neurokinin-1 receptor-expressing cells regulate depressor region of rat ventrolateral medulla. Am J Physiol Heart Circ Physiol 285:H2757–H2769
34. Zhang L, Vincent MA, Richards SM, Clerk LH, Rattigan S, Clark MG, Barrett EJ 2004 Insulin sensitivity of muscle capillary recruitment in vivo. Diabetes 53:447–453[Abstract/Free Full Text]
35. Vicent D, Ilany J, Kondo T, Naruse K, Fisher SJ, Kisanuki YY, Bursell S, Yanagisawa M, King GL, Kahn CR 2003 The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest 111:1373–1380[CrossRef][Medline]
36. Kim F, Gallis B, Corson MA 2001 TNF- inhibits flow and insulin signaling leading to NO production in aortic endothelial cells. Am J Physiol Cell Physiol 280:C1057–C1065
37. Kim F, Tysseling KA, Rice J, Pham M, Haji L, Gallis BM, Baas AS, Paramsothy P, Giachelli CM, Corson MA, Raines EW 2005 Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKß. Arterioscler Thromb Vasc Biol 25:1–6[Free Full Text]
38. Soos MA, Field CE, Siddle K 1993 Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J. 290(Pt 2):419–426
39. Langlois WJ, Sasaoka T, Yip CC, Olefsky JM 1995 Functional characterization of hybrid receptors composed of a truncated insulin receptor and wild type insulin-like growth factor 1 or insulin receptors. Endocrinology 136:1978–1986[Abstract]
40. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS 1994 Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int 45:598–604[Medline]
41. Fryburg DA, Jahn LA, Hill SA, Oliveras DM, Barrett EJ 1995 Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms. J Clin Invest 96:1722–1729
42. Bar RS, Boes M, Dake BL, Booth BA, Henley SA, Sandra A 1988 Insulin, insulin-like growth factors, and vascular endothelium. Am J Med 85:59–70[Medline]

This article has been cited by other articles:

				S. Erbel, C. Reers, V. W. Eckstein, J. Kleeff, M. W. Buchler, P. P. Nawroth, and R. A. Ritzel Proliferation of Colo-357 Pancreatic Carcinoma Cells and Survival of Patients With Pancreatic Carcinoma Are Not Altered by Insulin Glargine Diabetes Care, June 1, 2008; 31(6): 1105 - 1111. [Abstract] [Full Text] [PDF]

				G. Li, J.-P. del Rincon, L. A. Jahn, Y. Wu, B. Gaylinn, M. O. Thorner, and Z. Liu Growth Hormone Exerts Acute Vascular Effects Independent of Systemic or Muscle Insulin-like Growth Factor I J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1379 - 1385. [Abstract] [Full Text] [PDF]

				C. Lotton, D. Rodrigue, C. Elie, A. Rothenbuhler, N. Lahlou, C. Le Stunff, and P. Bougneres Akt Phosphorylation in Lymphocytes Provides an Index of in Vitro Insulin-Like Growth Factor I Sensitivity Associated with Growth Hormone-Induced Growth J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1458 - 1463. [Abstract] [Full Text] [PDF]

				H. Wang, A. X. Wang, Z. Liu, and E. J. Barrett Insulin Signaling Stimulates Insulin Transport by Bovine Aortic Endothelial Cells Diabetes, March 1, 2008; 57(3): 540 - 547. [Abstract] [Full Text] [PDF]

				U. Hiden, E. Glitzner, M. Ivanisevic, J. Djelmis, C. Wadsack, U. Lang, and G. Desoye MT1-MMP Expression in First-Trimester Placental Tissue Is Upregulated in Type 1 Diabetes as a Result of Elevated Insulin and Tumor Necrosis Factor-{alpha} Levels Diabetes, January 1, 2008; 57(1): 150 - 157. [Abstract] [Full Text] [PDF]

				L. Wang, T. C. Schulz, E. S. Sherrer, D. S. Dauphin, S. Shin, A. M. Nelson, C. B. Ware, M. Zhan, C.-Z. Song, X. Chen, et al. Self-renewal of human embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2 receptor signaling Blood, December 1, 2007; 110(12): 4111 - 4119. [Abstract] [Full Text] [PDF]

				Z. Liu Insulin at physiological concentrations increases microvascular perfusion in human myocardium Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1250 - E1255. [Abstract] [Full Text] [PDF]

				E. R. Duncan, S. J. Walker, V. A. Ezzat, S. B. Wheatcroft, J.-M. Li, A. M. Shah, and M. T. Kearney Accelerated endothelial dysfunction in mild prediabetic insulin resistance: the early role of reactive oxygen species Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1311 - E1319. [Abstract] [Full Text] [PDF]

				R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon Cardiovascular Actions of Insulin Endocr. Rev., August 1, 2007; 28(5): 463 - 491. [Abstract] [Full Text] [PDF]

				G. Li, E. J. Barrett, M. O. Barrett, W. Cao, and Z. Liu Tumor Necrosis Factor-{alpha} Induces Insulin Resistance in Endothelial Cells via a p38 Mitogen-Activated Protein Kinase-Dependent Pathway Endocrinology, July 1, 2007; 148(7): 3356 - 3363. [Abstract] [Full Text] [PDF]

				A. Denley, J. M. Carroll, G. V. Brierley, L. Cosgrove, J. Wallace, B. Forbes, and C. T. Roberts Jr. Differential Activation of Insulin Receptor Substrates 1 and 2 by Insulin-Like Growth Factor-Activated Insulin Receptors Mol. Cell. Biol., May 15, 2007; 27(10): 3569 - 3577. [Abstract] [Full Text] [PDF]

				W. Chai and Z. Liu p38 Mitogen-Activated Protein Kinase Mediates Palmitate-Induced Apoptosis But Not Inhibitor of Nuclear Factor-{kappa}B Degradation in Human Coronary Artery Endothelial Cells Endocrinology, April 1, 2007; 148(4): 1622 - 1628. [Abstract] [Full Text] [PDF]

				A. Fischoeder, H. Meyborg, D. Stibenz, E. Fleck, K. Graf, and P. Stawowy Insulin augments matrix metalloproteinase-9 expression in monocytes Cardiovasc Res, March 1, 2007; 73(4): 841 - 848. [Abstract] [Full Text] [PDF]

				G. S. Johansson and H. J. Arnqvist Insulin and IGF-I action on insulin receptors, IGF-I receptors, and hybrid insulin/IGF-I receptors in vascular smooth muscle cells Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E1124 - E1130. [Abstract] [Full Text] [PDF]

				R. Slaaby, L. Schaffer, I. Lautrup-Larsen, A. S. Andersen, A. C. Shaw, I. S. Mathiasen, and J. Brandt Hybrid Receptors Formed by Insulin Receptor (IR) and Insulin-like Growth Factor I Receptor (IGF-IR) Have Low Insulin and High IGF-1 Affinity Irrespective of the IR Splice Variant J. Biol. Chem., September 8, 2006; 281(36): 25869 - 25874. [Abstract] [Full Text] [PDF]

				J Ogino, K Sakurai, K Yoshiwara, Y. Suzuki, N Ishizuka, N Seki, Y. Suzuki, H Koseki, T Shirasawa, N Hashimoto, et al. Insulin resistance and increased pancreatic {beta}-cell proliferation in mice expressing a mutant insulin receptor (P1195L). J. Endocrinol., September 1, 2006; 190(3): 739 - 747. [Abstract] [Full Text] [PDF]

				H. Wang, Z. Liu, G. Li, and E. J. Barrett The vascular endothelial cell mediates insulin transport into skeletal muscle Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E323 - E332. [Abstract] [Full Text] [PDF]

				A. R. Gosmanov, F. B. Stentz, and A. E. Kitabchi De novo emergence of insulin-stimulated glucose uptake in human aortic endothelial cells incubated with high glucose Am J Physiol Endocrinol Metab, March 1, 2006; 290(3): E516 - E522. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 146/11/4690    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, G. Articles by Liu, Z. Search for Related Content